This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
by Zacks Equity Research
Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
7 Stocks With Triple-Digit Gains Powering S&P 500 ETF
by Sweta Killa
The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.
The Stock Market Rally Is Back In High Gear
by Daniel Laboe
All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
5 ETFs Sizzling to Start November
by Sweta Killa
ETFs overall gathered about $20 billion capital last week (ending Nov 5), bringing in inflows of more than $739 billion year to date.
Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially
Markets Up on COVID Pill News
by Zacks Equity Research
Markets Up on COVID Pill News
More Good Covid Treatment News; Markets Up Again
by Mark Vickery
The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.
Rally in Travel and Tourism ETFs Set to Continue
by Sweta Killa
The solid trend in travel and tourism ETFs are likely to continue heading into the holiday season given the reopening of domestic and international borders for traveling.
Stock Market News for Nov 8, 2021
by Zacks Equity Research
Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.
Three Encouraging News on U.S. Economic Recovery: 5 Top Picks
by Nalak Das
We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
by Zacks Equity Research
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Nonfarm Payrolls Jump in October
by Zacks Equity Research
Nonfarm Payrolls Jump in October.
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
Huge Jobs Number: 531K, 4.6% Unemployment; Did Pfizer Cure Covid?
by Mark Vickery
The private sector alone brought 604K jobs, more than a third of which came from the Leisure & Hospitality and Professional & Business Services sectors.
The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks
by Nalak Das
Each of our large-cap picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and has a VGM Score of A. These are: NUE, PFE, DOW, COST and LOW.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.